Xellar

Xellar develops an AI-based computational platform for drug discovery, combining microfluidic Organ-on-a-Chip technology with high-throughput screening, content imaging, and machine learning-based data analysis. The platform enables researchers to model human organ physiology in vitro and screen drug candidates with greater predictive accuracy than traditional cell culture or animal models. Founded in 2022 and headquartered in Cambridge, United States, Xellar has raised approximately $53.4M in Series A funding from investors including Zhen Fund, Legend Capital, Yayi Capital, Tiantu Investment, Qingsong Capital, GF Securities, and Oriental Fortune Capital. The company employs 28 people and addresses the high failure rate in drug development by providing more physiologically relevant preclinical models that integrate organ-level biology with computational analysis, enabling better candidate selection and toxicity prediction.